Aim: Tubeimoside-1 (TBMS1), a triterpenoid saponin extracted from the Chinese herbal medicine Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae), has shown anticancer activities in various cancer cell lines. The aim of this study was to investigate the anticancer activity and molecular targets of TBMS1 in human prostate cancer cells in vitro. Methods: DU145 and P3 human prostate cancer cells were treated with TBMS1. Cell viability and apoptosis were detected. ROS generation, mitochondrial membrane potential and cell cycle profile were examined. Western blotting was used to measure the expression of relevant proteins in the cells. Results: TBMS1 (5-100 μmol/L) significantly suppressed the viability of DU145 and P3 cells with IC 50 values of approximately 10 and 20 μmol/L, respectively. Furthermore, TBMS1 dose-dependently induced apoptosis and cell cycle arrest at G 0 /G 1 phase in DU145 and P3 cells. In DU145 cells, TBMS1 induced mitochondrial apoptosis, evidenced by ROS generation, mitochondrial dysfunction, endoplasmic reticulum stress, modulated Bcl-2 family protein and cleaved caspase-3, and activated ASK-1 and its downstream targets p38 and JNK. The G 0 /G 1 phase arrest was linked to increased expression of p53 and p21 and decreased expression of cyclin E and cdk2. Co-treatment with Z-VAD-FMK (pan-caspase inhibitor) could attenuate TBMS1-induced apoptosis but did not prevent G 0 /G 1 arrest. Moreover, co-treatment with NAC (ROS scavenger), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) or salubrinal (ER stress inhibitor) significantly attenuated TBMS1-induced apoptosis. Conclusion: TBMS1 induces oxidative stress-mediated apoptosis in DU145 human prostate cancer cells in vitro via the mitochondrial pathway.
Introduction
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide and is the second leading cause of cancer-related deaths in men [1] . Treatment options for prostate cancer principally include surgery, radiation therapy, hormone therapy and chemotherapy, depending on the stage of the disease and the characteristics of the patients [2] . Androgen deprivation therapy is still the primary treatment for prostate cancer patients. Although initially successful, this form of therapy frequently fails in the advanced stage of the disease, and patients develop castration-resistant prostate cancer, which is almost untreatable [1] . Surgery [1] and radiation [3] therapies are limited to localized prostate cancer. Thus, chemotherapy remains the only option for advanced-stage prostate cancer patients. Studies in recent years have shown that chemotherapeutic drugs, such as docetaxel and cabazitaxel, have improved the health status of prostate cancer patients; however, the prognosis of this disease is still very poor [4, 5] . Apoptosis is a highly synchronized process that plays a key role in tissue homoeostasis by selectively killing unwanted or cancerous cells. Inhibition of apoptosis results in tumorigenesis and chemo-resistance. Cancer cells achieve high proliferation rates by inhibiting apoptosis through various mechanisms [6] . Mitochondria are the major organelles involved in apoptosis and have been extensively studied in the last decade [7] . Reactive oxygen species (ROS) are produced in cells
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Tubeimoside-1 induces oxidative stress-mediated apoptosis and G 0 /G 1 phase arrest in human prostate carcinoma cells in vitro www.chinaphar.com Yang JB et al Acta Pharmacologica Sinica npg during normal oxidative metabolism, and cellular antioxidant systems neutralize them to maintain a redox balance. Overproduction of ROS has been shown to induce mitochondrial apoptosis. It has been established that cancer cells possess higher oxidative stress compared to normal cells to fulfill the demands of uncontrolled growth [1, 7] . Recent research has shown that natural bioactive compounds targeting ROS metabolism can selectively kill cancer cells by increasing the ROS level above a toxic threshold. As cancer cells contain higher levels of endogenous ROS, the toxic threshold can easily be achieved in cancer cells by targeting them with exogenous ROS-generating phytochemicals [1, 7, 8] . Prostate cancer cells have been reported to contain higher level of ROS [9] ; therefore, targeting ROS metabolism in prostate cancer cells may be an effective treatment.
Traditional Chinese herbal medicine is a good source of cancer chemotherapeutic agents [10] [11] [12] . Tubeimoside-1 (TBMS1) is a naturally occurring triterpenoid saponin that was isolated from Bolbostemma paniculatum (Maxim.) Franquet (Cucurbitaceae). TBMS1 has been shown to have potent cytotoxicity against several cancer cell lines, including human glioma U87 [13] , HepG2, esophageal squamous cell carcinoma EC109 [14] , ovarian cancer SKOV-3 [15] , CDDP-resistant A2780 [16] , choriocarcinoma JEG-3 [17] , lung cancer A549 [18] , cervical carcinoma HeLa [19] and BGC823 gastric cancer cells [20] . However, its effect on human prostate cancer remains unexplored.
In the present study, we investigated the cytotoxic effect of TBMS1 on human prostate carcinoma cells. We found that TBMS1 could potently inhibit the proliferation of prostate cancer cells via oxidative stress, and the inhibitory activity was linked to induction of several important apoptosis-related signaling pathways.
Materials and methods
Chemicals and reagents TBMS1 was purchased from the National Institutes for Food and Drug Control (Beijing, China), with >99% purity as confirmed by HPLC analysis. TBMS1 was dissolved in DMSO to generate a 20 mmol/L stock solution and stored at -80 °C. The stock solution was freshly diluted with culture medium before use, and the final concentration of DMSO was <1% in all experiments. The rabbit antihuman Bcl-2, Bax, p-p38, p53, CHOP, and p-JNK monoclonal antibodies were purchased from Beyotime (Shanghai, China); cyclin E, cdk2 and β-actin monoclonal antibodies were purchased from Boster (Wuhan, China); the p21 monoclonal antibody was purchased from ZSGB-Bio (Beijing, China); the p-ASK-1 monoclonal antibody was purchased from Santa Cruz (Santa Cruz, USA); the caspase inhibitor was purchased from Beyotime (Shanghai, China); a JNK inhibitor and p38 inhibitor were purchased from Sigma (Beijing, China). The thioredoxin antibody was purchased from Proteintech. Dulbecco's modified Eagle's medium (DMEM) and characterized grade fetal bovine serum (FBS) were purchased from HyClone (USA). Dimethyl sulfoxide (DMSO) was purchased from Sangon Biotech (Shanghai, Cell culture and treatments DU145 and PC3 human prostate cancer cell lines were purchased from the American Type Culture Collection (ATCC, China) and were routinely cultured in DMEM, supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in 5% CO 2 . Cells were treated with various concentrations of TBMS1 dissolved in dimethyl sulfoxide (DMSO) with a final DMSO concentration of 0.5%. DMSO-treated cells were used as a control.
Cell viability analysis
Cell viability was determined by the MTT assay as described previously [21] . Briefly, DU145 and PC3 cells were seeded in 96-well tissue culture plates and incubated in a CO 2 incubator for 24 h, and the cells were then exposed to different concentrations of TBMS1 (1-100 μmol/L) for 24 h. Following treatment, 10 μL MTT reagent (5 mg/mL) was added to each well, and cells were further incubated at 37 °C for 4 h. Subsequently, 150 μL DMSO was added to dissolve the formazan crystals, and absorbance was measured at 570 nm in a microplate reader (Thermo Scientific, Varioskan Flash, USA). The percentage cell viability was calculated as follows:
Cell viability (%)=(A 570 sample -A 570 blank )/(A 570 control -A 570 blank )×100
The IC 50 value was calculated using GraphPad Prism 5.
Observation of cell morphological changes DU145 and PC3 cells were treated with the indicated con centrations of TBMS1 in the presence or absence of 3 mmol/L of the ROS scavenger NAC for 24 h, and cell morphological changes were observed and photographed by a phase contrast microscope (Olympus 1×71, Japan) equipped with a CCD camera (Olympus DP72, Japan).
Nuclear morphological changes by Hoechst 33258 staining DU145 and PC3 cells were treated with different concentrations of TBMS1 for 24 h. Following treatment, cells were washed and fixed with 4% paraformaldehyde for 10 min at room temperature. After washing with PBS, cells were stained with Hoechst 33258 (50 μg/mL) and incubated at 37 °C for 20 min in the dark. Finally, the cells were washed and resuspended in PBS for the observation of nuclear morphology under a fluorescence microscope (Olympus 1×71, Japan) and photographed with a CCD camera (Olympus DP72, Japan). Apoptotic cells were defined as cells with nuclear shrinkage and chromatin condensation. Flow cytometric analysis of the cell cycle DU145 and PC3 cells were treated with different concentrations of TBMS1 for varying times in the presence or absence of 20 μmol/L Z-VAD-FMK. After harvesting and fixing with 70% ice-cold ethanol overnight, the cells were washed twice with PBS. The cell pellets were then resuspended in a solution containing 50 µg/mL PI and 100 µg/mL RNase A for 30 min in the dark at room temperature as described previously [22] . The DNA contents were analyzed by flow cytometry (Beckman Coulter, Epics XL) using Cell Quest software.
Determination of intracellular reactive oxygen species (ROS) generation TBMS1-induced ROS generation in DU145 cells was determined using the 2',7'-dichlorofluorescein-diacetate (DCFH-DA) staining method as described previously [21] . The DU145 cells were treated with different concentrations of TBMS1 for 24 h and then stained with DCFH-DA (10 μmol/L) at 37 °C for 30 min in the dark. The stained cells were then collected by centrifugation, washed 3 times with PBS, and resuspended in 200 µL PBS. The samples were analyzed for 2',7'-dichlorofluorescein (DCF) fluorescence with flow cytometry (Beckman Coulter, Epics XL, USA).
Determination of mitochondrial transmembrane potential (MMP) depolarization TBMS1-induced MMP depolarization in DU145 cells was assessed using rhodamine 123 (Rho123) as described previously [23] . The DU145 cells were treated with different concentrations of TBMS1 for 24 h. Following treatment, the cells were collected by centrifugation, washed with PBS twice and then stained with rhodamine 123 (10 μg/mL) at 37 °C for 30 min in dark. The stained cells were washed 3 times with PBS and resuspended in 200 µL PBS. Rhodamine 123 fluorescence was determined using flow cytometry (emission wavelength λ ex =488, excitation wavelength λ em =530).
Western blotting
The DU145 cells were treated with different concentrations of TBMS1 for 24 h in the presence or absence of SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and salubrinal (a selective inhibitor of ER stress). The cells were collected, and the protein was extracted as described previously [23] . Protein concentrations of the supernatants were determined using a BCA Protein Assay Kit. Approximately 40 μg of total proteins was separated on SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad Laboratories, Inc, USA). After blocking with 5% (w/v) nonfat milk and washing with Tris-buffered saline-Tween solution (TBST), membranes were incubated overnight at 4 °C with antibodies against thioredoxin (1:1000), p-ASK-1 (1:500), p38 (1:1000), p-JNK (1:1000), CHOP (1:1000), Bax (1:1000), Bcl-2, cleaved caspase-3 (1:1000), p53 (1:1000), p21 (1:100), cyclin E (1:200), cdk2 (1:400) and β-actin (1:400). After washing, the blots were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG secondary antibodies (1:5000) for 1 h at room temperature. After washing with TBST, signals were detected using an ECL Plus chemiluminescence kit with X-ray film (Millipore Corporation, Billerica, USA).
Statistical analysis
All data are expressed as the mean±SEM. One-way ANOVA was used to compare the control and test values. Student's t-test was used to determine significance when only two groups were compared. P values less than 0.05 were considered statistically significant.
Results

TBMS1 inhibits the proliferation of prostate cancer cells
To initially investigate the antiproliferative effect of TBMS1 ( Figure 1A ) on prostate cancer cells, DU145 and PC3 cells were exposed to different concentrations of the test compound for 24 h. Cell viabilities were determined using the MTT assay. As shown in Figure 1B and 2A, TBMS1 inhibited the proliferation of DU145 and PC3 cells in a dose-dependent manner, with IC 50 values of approximately 10 and 20 µmol/L, respectively. The cytotoxic effect of TBMS1 on cell morphology was also observed under a phase contrast microscope.
As shown in Figure 1D and 2C, TBMS1-treated cells displayed severe morphological changes indicating cell death, including rounding and shrinkage accompanied by decreased cell number. Pretreatment of the cells with 3 mmol/L NAC significantly inhibited the cytotoxic effect of TBMS1 in DU145 ( Figure 1E and 1C) and PC3 cells as shown in Figure 2D and 2B. These data indicate that TBMS1 induces oxidative stressmediated cell death in both DU145 and PC3 cells.
TBMS1 induces apoptotic cell death in prostate cancer cells Apoptosis and cell cycle arrest are considered the two major causes of cell growth inhibition. DNA fragmentation and loss of plasma membrane asymmetry are characteristic features of apoptotic cell death. First, we investigated the effects of TBMS1 on apoptosis of DU145 cells using an Annexin V-FITC/PI double staining kit and flow cytometry. The data showed that TBMS1 induced apoptosis in DU145 cells in a dose-and time-dependent manner as shown in Figure 3 . Pretreatment of the cells with 20 μmol/L Z-VAD-FMK, a pancaspase inhibitor, significantly inhibited the apoptotic effects of TBMS1, indicating that TBMS1 induces caspase-dependent apoptosis in DU145 cells ( Figure 3F ). The TBMS1-mediated apoptotic cell death was further confirmed using H33258 www.chinaphar.com Yang JB et al Acta Pharmacologica Sinica npg staining and fluorescence microscopy. As shown in Figure  3 , TBMS1 significantly induced chromatin condensation and nuclear fragmentation in DU145 cells in a dose-dependent manner. The apoptotic effect of TBMS1 was also assessed in PC3 androgen-independent prostate cancer cells. As shown in Figure 4 , TBMS1 induced dose-dependent apoptosis in PC3 cells in a similar fashion as observed in DU145 cells.
TBMS1 induces G 0 /G 1 phase arrest in prostate cancer cells To investigate the effects of TBMS1 on cell cycle distribution, the DU145 cells were treated with TBMS1, and the cell cycle profile was then assayed by flow cytometry using the PI staining method. The data demonstrated that TBMS1 induced cell cycle arrest at G 0 /G 1 phase in a dose-and time-dependent manner as shown in Figure 5A and 5C, respectively. Z-VAD-FMK, a broad-spectrum caspase inhibitor, had no effect on cell cycle arrest, indicating that cell cycle arrest is an apoptosisindependent event as shown in Figure 5C and 5D. Next, we determined whether TBMS1 could also induce cell cycle arrest at G 0 /G 1 phase in PC3 cells. For this, we treated PC3 cells with different concentrations of TBMS1 and analyzed the cell cycle profile. The data demonstrated that TBMS1 also caused G 0 / G 1 phase cell cycle arrest in PC3 cells ( Figure 4E and 4F) . As DU145 cells were found to be more sensitive to TBMS1 treatment, further studies were conducted using DU145 cells.
TBMS1 induces ROS generation and disrupts the MMP
The intracellular ROS generation in DU145 cells was mea- Figure 6A and 6B, the level of intracellular ROS in DU145 cells treated with 3, 9, and 15 μmol/L TBMS1 was 18.23%±1.26%, 26.88%±1.89% and 35.01%±1.07%, respectively. These values were significantly higher than the control group (2.97%± 0.04%). Mitochondria play key roles in the regulation of cell death and proliferation, and depolarization of the mitochondrial membrane potential (MMP) is a characteristic feature of apoptosis [24] . ROS generation has been reported to induce apoptosis by dissipating the MMP. We therefore investigated the effects of TBMS1 on MMP in DU145 cells. As shown in Figure  6C and 6D, treatment of the cells with 3, 9, and 15 µmol/L TBMS1 reduced the MMP from 95.03%±5.32% (control) to 94.98%±2.47%, 84.75%±7.01%, and 65.77%±4.22%, respectively.
TBMS1 activates ASK-1 and MAPK
Apoptosis signal-regulating kinase 1 (ASK-1) is a member of the mitogen-activated protein kinase (MAPK) kinase kinase family, which can be activated by phosphorylation at Thr845 in response to oxidative stress, ER stress and chemotherapeutic agents [25] . Activated ASK-1 has been shown to activate the c-Jun N-terminal kinase (JNK) and p38 pathways by direct phosphorylation. Therefore, we determined the effect of TBMS1 on the expression of these stress-activated proteins. The data showed that TBMS1 activates ASK-1 by inducing phosphorylation at Thr845 in a dose-dependent manner. TBMS1 treatment also induced phosphorylation of the ASK-1 downstream target proteins JNK and p38 in a dose-dependent manner as shown in Figure 7 . Because ASK-1 activation is associated with ER stress, we next asked if TBMS1 could (Figure 7 ). Because thioredoxin is bound to ASK-1 and negatively regulates its activation [25] , we therefore measured the expression of thioredoxin in response to TBMS1 treatment. As expected, TBMS1 treatment decreased the expression of thioredoxin in a dose-dependent manner (Figure 7 ).
TBMS1 induces apoptosis in DU145 cells via the mitochondrial pathway
Intracellular ROS generation and dissipation of the mitochondrial membrane potential are the characteristic features of mitochondrial apoptosis. Therefore, we measured the expression of Bcl-2 family proteins, which are the main mediators of mitochondrial apoptosis. As shown in Figure 8A and 8B, the TBMS1 treatment substantially increased the expression of Bax and decreased the expression of Bcl-2 in a dose-dependent manner. Moreover, TBMS1 induced the cleavage of caspase-3 in a dose-dependent manner. The data clearly indicate that TBMS1 induces mitochondrial apoptosis in DU145 cells.
TBMS1 up-regulates p53 and p21 expression and down-regulates cyclin E and cdk2 expression TBMS1 induced G 0 /G 1 phase arrest in DU145 cells. Therefore, we measured the expression of cell cycle regulators involved in the G 1 -S transition. p53, a tumor suppressor protein, has been shown to regulate cell cycle progression at G 0 /G 1 , as well as G 2 /M, phase by inducing the expression of its direct down- . Thus, we assayed the expression of p53 and p21 in response to TBMS1 treatment. The data showed that TBMS1 dose-dependently increased the expression of p53 and p21. Next, we assessed the expression of cyclin E and cdk2, which play important roles in the transition of the cell cycle from G 1 -S phase. As shown in Figure 8C and 8D, TBMS1 attenuated the expressions of cyclin E and cdk2 in a dosedependent fashion.
TBMS1 induces oxidative stress-mediated apoptosis in DU145 cells As TBMS1 induced the expression of oxidative stress-medi- www.nature.com/aps Yang JB et al Acta Pharmacologica Sinica npg ated proteins (p38, JNK, and CHOP) in DU145 cells, we next determined whether these proteins were involved in TBMS1-mediated apoptosis. For this, we evaluated the expression of Bax, Bcl-2, and cleaved caspase-3 following inhibition of the expressions of these stress-mediated proteins using pharmacological inhibitors. As shown in Figure 9 , pretreatment of the cells with SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and salubrinal (ER stress inhibitor) significantly reversed the TBMS1-mediated changes in the expression of Bax, Bcl-2, and caspase-3. These data indicate that TBMS1 induces oxidative stress-mediated apoptosis in DU145 cells.
Discussion
One of the major challenges in cancer chemotherapy is to identify new molecules that can eradicate cancer cells by inducing apoptosis. Apoptosis can be initiated either by activation and ligation of the death receptors to their respective ligands or by mitochondrial activation [26] . Cancer cells obtain their metabolic energy predominantly through glycolysis by altering the function of the mitochondria [27] . Mitochondria are a major component of the intrinsic apoptosis execution machinery and have been extensively studied [26, 28] . Because the activation of mitochondria has been recognized as a "milestone" in the apoptotic process, the manipulation of mitochondrial activation to initiate apoptotic cell death in cancer cells has been considered a potential therapeutic approach.
In the present study, we found for the first time that TBMS1 could effectively inhibit the growth of and induce mitochondrial apoptosis in DU145 cells through oxidative stress. Accumulating research suggests that cancer cells exhibit high oxidative stress compared with normal cells, which plays an important role in cancer cell survival, proliferation, disruption of cell death signaling, metastasis, angiogenesis, and drug resistance [29] [30] [31] . Recent research has shown that in contrast to the tumor-promoting ability of higher ROS levels, this biochemical property of cancer cells may have therapeutic benefits. Targeting mitochondria to increase the ROS level above a toxic threshold by exogenous ROS-generating phytochemicals to selectively kill cancer cells has been shown to be feasible in various in vitro and in vivo experimental models [29] [30] [31] [32] [33] . In the present study, TBMS1 increased ROS generation, modulated Bax and Bcl-2 expression, dissipated mitochondrial membrane potential and ultimately induced apoptosis in DU145 cells by inducing DNA fragmentation and caspase-3 cleavage in a dose-dependent manner. The data clearly demonstrate that TBMS1 induces mitochondrial apoptosis in DU145 cells.
ROS are also known to act as second messengers to activate diverse redox-sensitive signaling cascades, including MAPK family members and their downstream transcription factors [21] . Next, we determined whether TBMS1 could activate the stress-activated MAPK family proteins in DU145 cells. ASK-1 is a member of MAPK kinase kinase family, which is activated by phosphorylation at Thr845 in response to oxidative stress, ER stress and chemotherapeutic agents [25] . ASK-1 acts as an upstream activator of the JNK and p38 MAPK pathways [25] . Under non-stressed conditions, thioredoxin binds to ASK-1 and inhibits its activity. Under stress, ASK-1 becomes activated via phosphorylation of the Thr845 residue and dissociates from thioredoxin [25, 34] . Therefore, we determined the effect of TBMS1 on the expression of these stress-activated proteins. The data demonstrated that TBMS1 induced phosphorylation of ASK-1 and its downstream target proteins JNK and p38 and reduced the expression of thioredoxin in a dose-dependent manner. As ASK-1 is also associated with ER stress [25] , we therefore measured the expression of CHOP, a transcription factor that is induced during ER stress [35] . As expected, TBMS1 increased the expression of CHOP, indicating the involvement of ER stress in TBMS1-treated cells. These findings are further supported by a previous report showing that TBMS1 increased the expression of CHOP and phosphorylated p38 in SKOV-3 cells [16] . The JNK and p38 MAPK pathways have been reported to play important roles in activation of the mitochondrial apoptotic pathway [16, 36] . Next, we determined the functional link between stress-activated proteins and mitochondrial apoptosis regulators. To investigate the possible role of JNK, p38 and ER stress in TBMS1-induced apoptosis in DU145 cells, we measured the expression of Bcl-2, Bax, and cleaved caspase-3 in the presence or absence of specific pharmacological inhibitors. Pretreatment of the cells with SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and salubrinal (ER stress inhibitor) significantly reversed the TBMS1-mediated expression of Bax, Bcl-2, and caspase-3. The data show that TBMS1 induces oxidative stress-mediated apoptosis in DU145 cells.
Cell cycle arrest at a particular checkpoint is one of the major causes of cell death in cancer cells [26] . Many chemotherapeutic agents inhibit cell proliferation through activation of various intracellular signaling pathways to arrest the cell cycle at G 0 / G 1 , S, or G 2 /M phase [22] . p53, "the guardian of the genome," has been shown to induce cell cycle arrest at both G 0 /G 1 and G 2 /M phase by activating its direct downstream effector p21 [37, 38] . In the present study, TBMS1 arrested the cell cycle at G 0 /G 1 phase in a dose-dependent manner by increasing the expression of p53 and p21. To confirm the G 0 /G 1 phase arrest, we measured the expression of cyclin E and cdk2, which are involved in progression of the cell cycle from G 1 -S transition. Cells with suppressed cyclin E/cdk2 activity are arrested at G 0 /G 1 phase [39] . Consistent with the flow cytometry data indicating cell cycle arrest, TBMS1 decreased the expression of cyclin E and cdk2 in a dose-dependent manner. In contrast to the study of Yin et al [40] , who showed that TBMS1 induces G 2 / M arrest in HepG2 cells, TBMS1 arrested the cell cycle at G 0 / G 1 phase in DU145 cells. This incongruent data may be due to the different cancer cell types.
In conclusion, our data showed that TBMS1 effectively inhibited growth by inducing apoptosis and cell cycle arrest at G 0 /G 1 phase. This TBMS1-induced mitochondrial apoptosis was found to be associated with the activation of several upstream oxidative stress-mediated activators, such as ASK-1, p38, JNK, and CHOP. Supplementation of the cells with a p38 inhibitor, JNK inhibitor and ER stress inhibitor could effectively reduce the TBMS1-induced mitochondrial apoptosis www.chinaphar.com Yang JB et al Acta Pharmacologica Sinica npg regulator expression. Taken together, the data showed that TBMS1 induces oxidative stress-mediated apoptosis in DU145 cells.
